Abstract
Cytomegalovirus (CMV) infection is a major complication following solid organ transplantation resulting in significant morbidity and mortality. The guidelines published in 2004 have recommendations for therapy; however, the frequency of resistant CMV infection is increasing and therapy is not clearly defined. There are a few alternatives to ganciclovir such as foscarnet, cidofovir, and leflunomide; however, their use is limited by adverse effects. This report summarizes the successful use of high-dose ganciclovir for the treatment of a resistant CMV caused by UL97 mutation.
Original language | English (US) |
---|---|
Pages (from-to) | 129-132 |
Number of pages | 4 |
Journal | Transplant Infectious Disease |
Volume | 10 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2008 |
Externally published | Yes |
Keywords
- Cytomegalovirus
- Ganciclovir
- Resistance
- Transplant
- UL97 mutation
ASJC Scopus subject areas
- Infectious Diseases
- Transplantation